# Nephrology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fannie Lou Hamer (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML031-SYN-TD
- Date: 1967-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cornelius Agbaje, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Lorraine Batiste-Hill, MD

## Reason for consultation

Albumin in the urine and mildly reduced kidney function in a 49-year-old woman with newly diagnosed type 2 diabetes, high blood pressure readings awaiting home confirmation, and kidneys injured in a beating years ago. Please advise on the cause, the need for imaging, kidney-protective treatment, and monitoring. A telehealth visit from our health center is requested, because the trip to the regional hospital is long and she has no car. **S**

## History

Mrs. Hamer, 49, is seen by video from the community health center at the request of Dr. Batiste-Hill, with the community health worker beside her and her consent to the telehealth visit. She describes injuries to her kidneys and left eye from a beating years ago, and back and leg aching since. She has had thirst and frequent urination for some months, easing on metformin. Her home blood pressure readings over seven days average 152/94. She takes no NSAIDs. She has no blood in the urine, no kidney stones and no known family kidney disease. She said she would agree to treatment if each medicine and its purpose were explained, and asked what the medicines would cost. **S**

## Examination

| System | Finding |
|---|---|
| General | By video: comfortable and engaged, speaking in full sentences |
| Vital signs | Blood pressure 156/96 and pulse 82, measured by the clinic nurse today |
| Extremities | No ankle swelling, as examined by Dr. Batiste-Hill today |

BP 156/96 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 92.6 kg; BMI 34.9 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Batiste-Hill's intake note and results: creatinine 0.96 mg/dL, eGFR 73; potassium 4.3 mmol/L; urine albumin-to-creatinine ratio 88 mg/g at intake and 96 mg/g this morning; A1c 8.6%; LDL 146 mg/dL; ECG without left ventricular hypertrophy. Kidney ultrasound this morning: right kidney 9.0 cm with a lower-pole cortical scar, left kidney 11.4 cm and normal, no hydronephrosis or stones. Home blood pressure average 152/94; clinic 156/96 today. Urine albumin-to-creatinine ratio: 96 mg/g (high). All results are synthetic.

## Assessment

1. **Chronic kidney disease G2 A2** (N18.2). The small, scarred right kidney is a structural abnormality consistent with her old injury and is in itself chronic kidney disease; with an eGFR of 73 and albuminuria confirmed on two samples, she is G2 A2. Diabetes and high blood pressure probably add to the albumin loss. Nothing on ultrasound suggests blockage, stones or another cause, and no further imaging is needed. **S**
2. **Hypertension with chronic kidney disease** (I12.9). Stage 2 hypertension is confirmed by home readings. With albuminuria an ACE inhibitor is the foundation, and at this level two medicines together are recommended; a single combined capsule keeps cost and pill count down. Target below 130/80. **S**
3. **Type 2 diabetes with chronic kidney disease** (E11.22). An SGLT2 inhibitor protects the kidneys and heart at her eGFR and albuminuria, independent of its glucose effect. Metformin is safe at this eGFR at full dose. Finerenone is for albuminuria that persists despite an ACE inhibitor at the dose she tolerates and an SGLT2 inhibitor, and can wait. **S**

## Recommendations

1. Amlodipine 5 mg with benazepril 20 mg as one daily capsule; blood pressure goal below 130/80, with home readings.
2. Dapagliflozin 10 mg daily, at the health center's discount pharmacy price; stop it, with benazepril, on days of vomiting, diarrhea or not eating, and restart when eating and drinking again.
3. Potassium and creatinine one to two weeks after starting, accepting a creatinine rise of up to 30%; then every six months, scheduled on days she is already at the health center.
4. Urine albumin-to-creatinine ratio again in three to four months, then every six months; aim for at least a 30% fall.
5. Continue metformin and atorvastatin; avoid ibuprofen, naproxen and other NSAIDs, and tell any clinician about her kidneys before contrast dye.
6. No further imaging; repeat the ultrasound only if kidney function falls unexpectedly.
7. If albumin stays moderately increased after six months on both medicines, review by telehealth about increasing benazepril or adding finerenone.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Batiste-Hill by phone after the video visit. Each medicine, its purpose, its cost and its side effects were explained to Mrs. Hamer, who asked questions and agreed to start both; she was told she could stop either at any time and should call first if she wanted to. **S**

## Follow-up

Telehealth review after six months of treatment if albumin remains raised, or sooner for a fall in eGFR of more than 30%, potassium above 5.5 mmol/L, or blood pressure not at goal on two medicines; Dr. Batiste-Hill continues care and monitoring. **S**

## Guideline basis

- Introduction and Methodology: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026), American Medical Association
